Cost-effectiveness acceptability curves revisited

PharmacoEconomics

Volumn 31, Issue 2, 2013, Pages 93-100

  Al, Maiwenn J ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONFIDENCE INTERVAL; COST EFFECTIVENESS ACCEPTABILITY CURVE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE SYSTEM; MONTE CARLO METHOD; NORMAL DISTRIBUTION; NULL HYPOTHESIS; PLOTS AND CURVES; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; UNCERTAINTY;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DECISION MAKING; DECISION SUPPORT TECHNIQUES; HUMANS; MODELS, ECONOMIC; MODELS, THEORETICAL;

EID: 84876239256     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-012-0011-8     Document Type: Article

References (38)

1. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3(5):309-19.
2. O'Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994;32:150-63.
3. Wakker P, Klaassen MP. Confidence intervals for cost/effectiveness ratios. Health Econ. 1995;4(5):373-81.
4. Sacristan JA, Day SJ, Navarro O, et al. Use of confidence intervals and sample size calculations in health economic studies. Ann Pharmacother. 1995;29:719-25.
5. Fieller EC. Some problems in interval estimation. J R Stat Soc Ser B Methodol. 1954;16(2):175-85.
6. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med. 1996;15:1447-58.
7. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall; 1993.
8. Polsky D, Glick HA, Willke R, et al. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ. 1997;6:243-52.
9. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 1998;7:723-40.
10. Meckley LM, Greenberg D, Cohen JT, et al. The adoption of cost-effectiveness acceptability curves in cost-utility analyses. Med Decis Making. 2010;30(3):314-9.
11. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making. 1990;10(3):212-4.
12. Weinstein MC, Zechhauser R. Critical ratios and efficient allocation. J Public Econ. 1973;2:147-57.
13. Cleemput I, Neyt M, Thiry N, et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care. 2011;27(1):71-6.
14. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.
15. Raftery J. Should NICE's threshold range for cost per QALY be raised? No. BMJ. 2009;338:b185.
16. Towse A. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ. 2009;338:b181.
17. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making. 1985;5(2):157-77.
18. Briggs AH, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy. 1998;3(4):233-45.
19. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2 Suppl.):S68-80.
20. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves: facts, fallacies and frequently asked questions. Health Econ. 2004;13(5):405-15.
21. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779-87.
22. Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ. 1999;8(3):191-201.
23. Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11(5):886-97.
24. Löthgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ. 2000;9(7):623-30.
25. Groot Koerkamp B, Hunink MG, Stijnen T, et al. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making. 2007;27(2):101-11.
26. Fenwick E, Briggs A. Cost-effectiveness acceptability curves in the dock: case not proven? Med Decis Making. 2007;27(2):93-5.
27. Jakubczyk M, Kaminski B. Cost-effectiveness acceptability curves: caveats quantified. Health Econ. 2010;19(8):955-63.
28. Sadatsafavi M, Najafzadeh M, Marra C. Technical note: acceptability curves could be misleading when correlated strategies are compared. Med Decis Making. 2008;28(3):306-7.
29. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ. 1999;8(3):257-61.
30. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341-64.
31. Al MJ, Feenstra TL, van Hout BA. Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. Health Econ. 2005;14(7):655-67.
32. Al MJ, Feenstra T, Brouwer WB. Decision makers' views on health care objectives and budget constraints: results from a pilot study. Health Policy. 2004;70(1):33-48.
33. Arrow K, Lind A. Uncertainty and the evaluation of public investment decisions. Am Econ Rev. 1970;60:364-78.
34. Palmer S, Smith PC. Incorporating option values into the economic evaluation of health care technologies. J Health Econ. 2000;19(5):755-66.
35. Griffin SC, Claxton KP, Palmer SJ, et al. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ. 2011;20(2):212-24.
36. Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med Decis Making. 2008;28(1):21-32.
37. Hoomans T, Fenwick EA, Palmer S, et al. Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer. Value Health. 2009;12(2):315-24.
38. Eckermann S, Willan AR. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. Pharmacoeconomics. 2011;29(7):563-77.